MedTrace Logo

Hemodynamic Management Following Acute Traumatic Spinal Cord Injury

NCT06451133 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2024-12-11

No results posted yet for this study

Summary

The purpose of this study is to assess the effect of various hemodynamic management strategies on functional neurologic outcomes and non-neurologic adverse events in the first 5 days following acute spinal cord injury (SCI). The hemodynamic management strategies assessed include targeting a mean arterial blood pressure (MAP) goal of 85-90 mmHg, targeting a spinal cord perfusion pressure (SCPP) goal of ≥65 mmHg, or targeting normal hemodynamics, which is a MAP goal of ≥65 mmHg.

Conditions

  • Spinal Cord Injuries

Interventions

OTHER

Mean arterial blood pressure (MAP) goal of ≥65 mmHg

The treatment team will maintain MAP ≥65 mmHg for the first five days following injury.

OTHER

Mean arterial blood pressure (MAP) goal of 85-90 mmHg

The treatment team will maintain MAP 85-90 mmHg for the first five days following injury.

OTHER

Spinal cord perfusion pressure (SCPP) goal of ≥65 mmHg

The treatment team will maintain SCPP ≥65 mmHg for the first five days following injury.

Sponsors & Collaborators

  • Trauma Research and Combat Casualty Care Collaborative (TRC4)

    collaborator UNKNOWN

  • The University of Texas Health Science Center, Houston

    lead OTHER

Principal Investigators

  • David Meyer, MD, MS, FACS · The University of Texas Health Science Center, Houston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-03
Primary Completion
2025-09-15
Completion
2026-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06451133 on ClinicalTrials.gov